A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2
Completed
NCT05613088
| Condition | Neoplasms, Ovarian |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Bristol-Myers Squibb |
|---|
| Status | Completed |
|---|
| Enrollment | 106 participants |
|---|
| Interventions | MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan |
|---|
| Start date | Feb 1, 2023 |
|---|
| Completion date | Jun 17, 2024 |
|---|
| Results posted | Jul 3, 2025 |
|---|
Summary
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment
From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 70 weeks) · Percent of participants
| MORAb-202 | 20.0 Percent of participants |
|---|
| Investigator's Choice (IC) Chemotherapy | 13.9 Percent of participants |
|---|
Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose
From first dose of study medication up to 6 months · Participants
| MORAb-202 | 2 Participants |
|---|
| Investigator's Choice (IC) Chemotherapy | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.